SFL is happy to share two articles ​exploring the potential impact of different Brexit scenarios regarding:

• Disclosure of Clinical Trials Data  in the context of commercially confidential information, informed consent forms, rights of trial subjects and disclosure of information between the then separated jurisdictions of post-Brexit UK and the EU-27.

• Privacy Law in Clinical Trials Data Exchange  on the interplay of the upcoming Clinical Trials Regulation with the General Data Protection Regulation, as well as the new regulatory measures brought along.

These two articles analyse the potential Brexit impact on the conduct of clinical trials depending on the extent of alignment or divergence between a post-Brexit UK and the EU-27. This comes right in time when forthcoming negotiations and EU Summits turn into the hot phase of shaping the final Brexit scenario.

Brexit Impact Assessment Part A – Disclosure of Clinical Trials Data

Brexit Impact Assessment Part B – Privacy Law & Data Exchange